ROIVW | Roivant Sciences Ltd. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	2.6300 - 2.8600
52 Week Range	2.6300 - 2.8600
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	37,827
Average Volume	N/A
Shares Outstanding	3,176,509,090
Market Cap	8,735,399,998
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-09-27

Valuation
Profitability
Growth
Health
P/E Ratio	-0.67
Forward P/E Ratio	N/A
EPS	-4.09
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	620
Country	UK
Website	ROIVW

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

ROIVW's peers: PIIIW, PROCW, SABSW, MAIA, SATLW, TOIIW, PRENW, HUMAW, SEATW, JSPRW, NAMSW

*Chart delayed

Analyzing fundamentals for ROIVW we got that it has weak fundamentals where Valuation is considered to be overvalued, Profitability is very wealthy, Growth is desperately bad and Health is weak. For more detailed analysis please see ROIVW Fundamentals page.

Watching at ROIVW technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on ROIVW Technicals page.